AstraZeneca

In News

Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial - AstraZeneca

AstraZeneca - Apr 21, 2026

Germany risks missing out on new drugs, AstraZeneca CEO tells paper - Reuters

Reuters - Apr 21, 2026

Calamos Wealth Management LLC Invests $2.90 Million in Astrazeneca Plc $AZN - MarketBeat

MarketBeat - Apr 25, 2026

AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win - Fierce Pharma

Fierce Pharma - Apr 21, 2026

AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win - Fierce Biotech

Fierce Biotech - Apr 20, 2026

AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data - Clinical Trials Arena

Clinical Trials Arena - Apr 22, 2026

Why Gratitude Is Good Medicine - Medscape

Medscape - Apr 24, 2026

Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics - Yahoo Finance

Yahoo Finance - Apr 24, 2026

At AACR, talk of Chinese biotech, oncology’s comms issue, and more - statnews.com

statnews.com - Apr 22, 2026

AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth - ChartMill

ChartMill - Apr 24, 2026

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - AstraZeneca

AstraZeneca - Apr 20, 2026

AstraZeneca (NYSE: AZN) board member Rene Haas to step down - Stock Titan

Stock Titan - Apr 23, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment